Literature DB >> 22760537

Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.

Kecia N Carroll1, Marie R Griffin, Kathryn M Edwards, Asad Ali, Yuwei Zhu, Marika K Iwane, Peter G Szilagyi, Mary A Staat, Timothy P Stevens, Caroline B Hall, John V Williams, Tina V Hartert.   

Abstract

Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 U.S. counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22760537      PMCID： PMC3773819          DOI： 10.1097/INF.0b013e318266bf89

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  11 in total

1.  Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

Authors:  Lauren J Stockman; Aaron T Curns; Larry J Anderson; Gayle Fischer-Langley
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

2.  Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.

Authors:  Christian Hampp; Arwa S Saidi; Almut G Winterstein
Journal:  J Pediatr       Date:  2010-03-10       Impact factor: 4.406

3.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

4.  Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.

Authors:  T G Boyce; B G Mellen; E F Mitchel; P F Wright; M R Griffin
Journal:  J Pediatr       Date:  2000-12       Impact factor: 4.406

Review 5.  A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Authors:  Michael P Frogel; Dan L Stewart; Michael Hoopes; Ancilla W Fernandes; Parthiv J Mahadevia
Journal:  J Manag Care Pharm       Date:  2010 Jan-Feb

6.  The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.

Authors:  Behnoosh Afghani; Thienkim Ngo; Szu-Yun Leu; Fu L Wu; Maricel Cecilio; Pamela Aron-Johnson; Raja Zeitany; Jack Sills; Alpesh Amin
Journal:  Pediatr Infect Dis J       Date:  2006-11       Impact factor: 2.129

7.  Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1998-11       Impact factor: 7.124

8.  Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

Authors: 
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

9.  Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women.

Authors:  K M Neuzil; G W Reed; E F Mitchel; L Simonsen; M R Griffin
Journal:  Am J Epidemiol       Date:  1998-12-01       Impact factor: 4.897

10.  The burden of respiratory syncytial virus infection in young children.

Authors:  Caroline Breese Hall; Geoffrey A Weinberg; Marika K Iwane; Aaron K Blumkin; Kathryn M Edwards; Mary A Staat; Peggy Auinger; Marie R Griffin; Katherine A Poehling; Dean Erdman; Carlos G Grijalva; Yuwei Zhu; Peter Szilagyi
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245
View more
  2 in total

1.  Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

Authors:  John P DeVincenzo; Christopher S Ambrose; Doris Makari; Leonard B Weiner
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

2.  Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.

Authors:  Danielle B L Oliveira; Marika K Iwane; Mila M Prill; Geoffrey A Weinberg; John V Williams; Marie R Griffin; Peter G Szilagyi; Kathryn M Edwards; Mary A Staat; Caroline B Hall; Edison L Durigon; Dean D Erdman
Journal:  J Clin Virol       Date:  2015-01-24       Impact factor: 3.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.